Closing In on the Malaria Genome

Researchers have practically finished sequencing the most deadly form of the malaria parasite, Plasmodium falciparum. The project, started in 1996, will publish on its current standing late this summer, says Malcolm Gardner, associate investigator, parasite genomics group, at The Institute for Genomic Research (TIGR) in Rockville, Md. "I would say we have over 99% of the genome in the database," says Gardner. He made his comments at the annual meeting in February of the American Association for

Written byBrendan Maher
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

The 25-megabase genome has not come easy. It's nearly 80% A-T rich, meaning that long stretches of adenine and thymine confound efforts to tally base pairs. The group, which includes collaborators at TIGR, the Sanger Centre, and Stanford University, has completed five of the organism's 14 chromosomes, but about 500 gaps remain—a majority of which reside in three particularly troublesome chromosomes. An estimated 40% to 50% of p. falciparum's 5,600-some-odd genes have no homologs in other organisms, and many have strange features such as interruptions in known functional binding domains.

These features may offer clues to the biology of malaria. Michael Ferdig, assistant professor, Notre Dame University, says, "The tantalizing bit is that we'll discover the malarial parasite has a distinct way of operating, a distinct way of evolving. Common sense tells you that's usually not the case, but these are the kinds of questions you can't start to answer ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies